157 related articles for article (PubMed ID: 15950650)
41. Association between premenopausal progestogen use and postmenopausal hormonal therapy in the GAZEL cohort.
Ringa V; Fritel X; Varnoux N; Zins M; Piault S; Quelen C
Maturitas; 2007 Nov; 58(3):216-25. PubMed ID: 17919857
[TBL] [Abstract][Full Text] [Related]
42. Spanish post-menopausal women's viewpoints on hormone therapy.
Castelo-Branco C; Ferrer J; Palacios S; Cornago S; Peralta S
Maturitas; 2007 Apr; 56(4):420-8. PubMed ID: 17174045
[TBL] [Abstract][Full Text] [Related]
43. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms.
Lindh-Astrand L; Bixo M; Hirschberg AL; Sundström-Poromaa I; Hammar M
Menopause; 2010; 17(1):72-9. PubMed ID: 19675505
[TBL] [Abstract][Full Text] [Related]
44. Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up.
Barbaglia G; Macià F; Comas M; Sala M; del Mar Vernet M; Casamitjana M; Castells X
Menopause; 2009; 16(5):1061-4. PubMed ID: 19369903
[TBL] [Abstract][Full Text] [Related]
45. Gynecologists' attitudes towards hormone therapy in the post "Women's Health Initiative" study era.
Nassar AH; Abd Essamad HM; Awwad JT; Khoury NG; Usta IM
Maturitas; 2005 Sep; 52(1):18-25. PubMed ID: 16143222
[TBL] [Abstract][Full Text] [Related]
46. Duration of vasomotor symptoms in middle-aged women: a longitudinal study.
Col NF; Guthrie JR; Politi M; Dennerstein L
Menopause; 2009; 16(3):453-7. PubMed ID: 19188852
[TBL] [Abstract][Full Text] [Related]
47. Discontinuation of postmenopausal hormone therapy.
Grady D; Sawaya GF
Am J Med; 2005 Dec; 118 Suppl 12B():163-5. PubMed ID: 16414343
[TBL] [Abstract][Full Text] [Related]
48. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
Brinton RD
Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
[TBL] [Abstract][Full Text] [Related]
49. Understanding physicians' attitudes towards hormone therapy.
Hess R; Chang CC; Conigliaro J; McNeil M
Womens Health Issues; 2005; 15(1):31-8. PubMed ID: 15661585
[TBL] [Abstract][Full Text] [Related]
50. Personal use of hormone therapy by postmenopausal women doctors and male doctors' wives in Italy after the publication of WHI trial.
Biglia N; Ujcic E; Kubatzki F; Sgandurra P; Robba C; Ponzone R; Sismondi P
Maturitas; 2006 May; 54(2):181-92. PubMed ID: 16330170
[TBL] [Abstract][Full Text] [Related]
51. Recent reversal of trends in hormone therapy use in a European population.
Morabia A; Costanza MC
Menopause; 2006; 13(1):111-5. PubMed ID: 16607106
[TBL] [Abstract][Full Text] [Related]
52. Women's use of hormone therapy before and after the Women's Health Initiative: a psychosocial model of stability and change.
Gerend MA; Aiken LS; Erchull MJ; Lapin A
Prev Med; 2006 Sep; 43(3):158-64. PubMed ID: 16750263
[TBL] [Abstract][Full Text] [Related]
53. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study.
Lindh-Astrand L; Brynhildsen J; Hoffman M; Hammar M
Menopause; 2009; 16(6):1213-7. PubMed ID: 19455070
[TBL] [Abstract][Full Text] [Related]
54. Hormone therapy and breast cancer: what factors modify the association?
Gertig DM; Fletcher AS; English DR; Macinnis RJ; Hopper JL; Giles GG
Menopause; 2006; 13(2):178-84. PubMed ID: 16645531
[TBL] [Abstract][Full Text] [Related]
55. Vasomotor symptoms and mortality: the Rancho Bernardo Study.
Svartberg J; von Mühlen D; Kritz-Silverstein D; Barrett-Connor E
Menopause; 2009; 16(5):888-91. PubMed ID: 19421076
[TBL] [Abstract][Full Text] [Related]
56. Emerging facade of menopausal hormone therapy.
Rees M
Semin Reprod Med; 2010 Sep; 28(5):351-9. PubMed ID: 20845235
[TBL] [Abstract][Full Text] [Related]
57. Attitudes and practices about postmenopausal hormone therapy among female gynecologists in Brazil.
Filho AS; Soares Júnior JM; Arkader J; Maciel GA; Baracat EC
Maturitas; 2005 Jun; 51(2):146-53. PubMed ID: 15917155
[TBL] [Abstract][Full Text] [Related]
58. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
Salpeter S
Climacteric; 2005 Dec; 8(4):307-10. PubMed ID: 16390764
[TBL] [Abstract][Full Text] [Related]
59. Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort.
Engel P; Fabre A; Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
Am J Epidemiol; 2011 Jul; 174(1):12-21. PubMed ID: 21555715
[TBL] [Abstract][Full Text] [Related]
60. Provider management of menopause after the findings of the Women's Health Initiative.
Rolnick SJ; Jackson J; Kopher R; Defor TA
Menopause; 2007; 14(3 Pt 1):441-9. PubMed ID: 17318028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
